EPHX1 enhances drug resistance to regorafenib by activating the JAK/STAT signaling pathway in hepatocellular carcinoma cell lines.

ABSTRACT:

Background

Regorafenib serves as a second-line treatment for patients with advanced hepatocellular carcinoma (HCC). Microsomal epoxide hydrolase 1 (EPHX1) is closely associated with tumorigenesis and drug resistance. However, the relationship between EPHX1 and regorafenib resistance, as well as the underlying mechanisms in HCC, remains unclear.

Objective

To investigate the role and mechanisms of EPHX1 in mediating regorafenib resistance in HCC.

Methods

We assessed the protein expression levels of EPHX1 in human HCC tissues and adjacent non-tumor tissues. Subsequently, we constructed HCC cell lines with EPHX1 overexpression and knockdown using lentiviral vectors and stimulated these cells with varying concentrations of regorafenib. We then measured cell proliferation a

SUBMITTER: Xu B 

PROVIDER: S-EPMC12315303 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature